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d Shikoku MycobacteriaSummary A prospective study of the clinical efficacy of an aminoglycoside
antibiotic (streptomycin, SM) for the treatment of pulmonary Mycobacterium avium
complex (MAC) disease was carried out. In a multicenter trial, patients with
pulmonary MAC disease received protocol-guided combined chemotherapy with or
without SM. SM was given to the patients intramuscularly 15mg/kg three times per
week for the initial 3 months and three other antibiotics (rifampicin, ethambutol,
and clarithromycin) were added and administered for over 24 months after the
conversion of MAC strains. From April 1998 to December 2004, 160 HIV-negative
patients were enrolled in this trial. Fourteen patients were found to be ineligible
because they could not continue the treatment, and they were excluded from the
analysis after randomization. Seventy-three patients were assigned to receive
combined chemotherapy with SM (group A) and 73 were assigned to receive
combined chemotherapy without SM (group B). The median durations of treatment
were 27.6 months in group A and 28.4 months in group B. The difference in the
backgrounds of the groups was not statistically significant. There were no
differences in microbiological and radiological findings between the groups, but
the sputum conversion rate for pulmonary MAC disease at the completion of
treatment was significantly higher in group A than that in group B. Although, there
were no significant differences in the sputum relapse rate and clinical improvement
including both clinical symptoms and radiological findings, group A showed better
initial microbiological response than group B. As for adverse reactions and abnormal
laboratory findings, there were no significant differences between the groups.Elsevier Ltd. All rights reserved.
462 1111; fax: +81 86 464 1041.
asaki-m.ac.jp (Y. Kobashi).
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Combined therapy for pulmonary Mycobacterium avium complex disease 131Based on the results of this double-blind randomized study, we support treatment
including SM according to both the American Thoracic Society (ATS) and the
Japanese Society for Tuberculosis (JST) guidelines for patients with pulmonary MAC
disease without HIV infection.
& 2006 Elsevier Ltd. All rights reserved.Introduction
Pulmonary Mycobacterium avium complex (MAC)
disease is the most common nontuberculous myco-
bacterial infectious disease in Japan and is increasing
in incidence.1 Regarding its treatment, Wallace et al.
initiated a clinical trial of regimens including
rifabutin (RBT) or rifampicin (RFP), ethambutol
(EB), clarithromycin (CAM), and initial streptomycin
(SM), and reported that this regimen achieved
satisfactory results.2 In 1997, the American Thoracic
Society (ATS) recommended a four-drug regimen
including CAM or azithromycin (AZM), RFP or RBT, EB,
and an initial aminoglycoside (streptomycin) for
pulmonary MAC disease.3 Thereafter, in 1998, the
Japanese Society for Tuberculosis (JST) also recom-
mended a four-drug regimen including CAM, RFP, EB,
and an initial aminoglycoside.4 Recently, although
there have been several reports on combined
therapy including an aminoglycoside (SM or kanamy-
cin (KM)), there are no data comparing CAM contain-
ing regimens with and without an aminoglycoside
antibiotic. Therefore, we prospectively investigated
randomized trials of the conversion of MAC strains in
two groups treated with and without SM for over 24
months to investigate the clinical efficacy of this
aminoglycoside for pulmonary MAC disease.Patients and methods
Patients
From April 1998 to December 2004, 160 eligible
patients were enrolled in this randomized, double-
blind, placebo-controlled trial, which was con-
ducted at Kawasaki Medical School Hospital and
ten hospitals belonging to the Research Committee
of Mycobacterium in the Chugoku and Shikoku
areas. A regional institutional review board ap-
proved the protocol, and written informed consent
was obtained from all participants or their author-
ized representatives.
Selection criteria
Selection for this study required that patients
satisfy the ATS diagnostic criteria for nontubercu-lous mycobacterial infection,3 and that they have
negative serological findings for HIV or the absence
of obvious risk factors for that disease were
required.
The inclusion criteria for this trial were positive
sputum cultures for MAC at entry into the study,
and availability for an interval of treatment of over
24 months after the conversion of MAC strains.
Fourteen patients who could not undergo treat-
ment for over 24 months after the conversion of
MAC strains were excluded. The clinical features of
the 146 remaining patients were age, gender,
smoking and alcoholic history, underlying diseases
involving corticosteroid administration, clinical
symptoms (continuous cough, weight loss (X5 kg
during 3 months), hemosputum or hemoptysis, and
fever), microbiological findings, radiological find-
ings, clinical efficacy, and adverse reactions includ-
ing abnormal laboratory findings.Treatment assignments (Table 1)
Patients were randomly assigned in a 1:1 manner to
receive a streptomycin intramuscular injection
with other antituberculous drugs (group A) or only
the other antituberculous drugs (group B) at each
hospital. Randomization schemes were generated
in blocks of 11 for each participating site by a
central randomization center. The randomization
assignments were sent to the recruiting center in
sealed envelopes. The patients and the investiga-
tors were blinded to the patients’ treatment
assignments. SM was given to group A intramuscu-
larly 15mg/kg (500–1000mg) with 10% NaCl (na-
trium sodium) 1ml three times per week for the
initial 3 months along with RFP 10mg/kg/day
(350–650mg), EB 15mg/kg/day (500–1000mg),
and CAM 15mg/kg/day (500–1000mg), whereas
group B was given only 10% NaCl 1ml intramuscu-
larly (placebo control) without SM, but with RFP
10mg/kg/day (350–650mg), EB 15mg/kg/day
(500–1000mg), and CAM 15mg/kg/day (500–
1000mg). The overall treatment period was over
24 months after the conversion of MAC strains for
patients who routinely showed severe adverse
reactions.
ARTICLE IN PRESS
Table 1 Randomized treatment regimen for pulmonary MAC disease (146 cases).
(A) RFP 10mg/kg/day+EB 15mg/kg/day+CAM 15mg/kg/day+10%NaCl 1ml with SM 15mg/kg/3 times/week
(73 cases)
(B) RFP 10mg/kg/day+EB 15mg/kg/day+CAM 15mg/kg/day+10%NaCl 1ml without SM (placebo)/3 times/week
(73 cases)
RFP: rifampicin, EB: ethambutol, CAM: clarithromycin, SM: streptomycin NaCl: Natrium sodium.
Y. Kobashi et al.132Microbiological examination
Routine expectorated sputum was submitted for
examination by Ziehl–Neelsen staining on three
consecutive days at entry into the randomized
trial. Specimens submitted for culture were di-
gested and decontaminated by the sodium hydro-
xide method, and the samples were identified and
differentiated by growth characteristics and con-
ventional biochemical tests. Mycobacterium avium
and Mycobacterium intracellulare were identified
by the Amplicor polymerase reaction (PCR) assay
(Roche Diagnostic Systems, Inc., Branchburg, NJ).
Patients were examined every 2 weeks for the first
3 months, every 4 weeks thereafter during the
therapy, and at least every 2 months during the
follow-up after the completion of the therapy.
Sputum was submitted for examination at every
visit.
Radiological and laboratory examination
Computed tomography (CT) was performed initially
in all patients and every 3 months thereafter to
evaluate lesions, including cavities and bronchiec-
tasis, and underlying pulmonary conditions. A chest
roentogenograph was taken initially and every
month thereafter. Extension of lesions was evalu-
ated on the basis of both chest roentogenographs
and chest CT findings. A peripheral blood cell count
was performed and aminotransferase, total bilir-
ubin and serum creatinine were measured at each
visit during the therapy. Patients were advised to
consult an otolaryngologist and an ophthalmologist
initially, and as needed thereafter. A visual activity
test, perimetry, and a red–green color discrimina-
tion test were routinely performed every month to
check for EB toxicity.
Assessment of microbiological efficacy
Sputum conversion was defined as three consecu-
tive negative sputum cultures within 6 months,
with the time of conversion defined as the date of
the first negative culture. If the patient could notexpectorate sputum during the treatment duration,
the sputum was considered to have converted to
negative. The sputum relapse rate was defined as
two consecutive positive cultures after sputum
conversion.Assessment of clinical efficacy
Clinical efficacy was evaluated on the basis of
clinical improvement including both clinical symp-
toms (ones which were considered comparatively
characteristic for active pulmonary MAC disease
such as continuous cough, weight loss (X5 kg during
3 months), hemosputum or hemoptysis, fever) and
radiological findings, and the opinions of several
attending respiratory specialists were inserted. The
treatment regimen of each patient was blinded for
these attending respiratory specialists. Clinical
improvement was defined as follows: (1) ‘‘improv-
ing’’ if both abnormal shadows had decreased
within half of the lesion before treatment and
clinical improvement of any clinical symptoms was
found; namely, a decrease in continuous cough,
normalization of weight loss or body temperature,
or diminishment of hemoptysis or hemosputum, (2)
‘‘worsening’’ if both abnormal shadows had in-
creased compared with the lesion before treatment
and any clinical symptoms had increased, and (3)
‘‘unchanging’’ consisted of all patients except the
patients who clinical efficacy was defined ‘‘improv-
ing’’ and ‘‘worsening’’.Drug susceptibility
The MAC isolates obtained at entry were stored in
an 85% 7H9 medium: 15% glycerol at 80 1C.
Minimal inhibitory concentrations (MICs) to SM
were determined by microdilution using twofold
drug dilutions in Middlebrook 7H9 broth (pH
corrected to 7.4) or dextrose (OAD), as previously
described.5 Isolates were interpreted as SM-suscep-
tible if they had MICs of 2 mg/ml or less and
resistant if they had MICs of 44 mg/ml. Values of
2–4 mg/ml were considered intermediate.
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Combined therapy for pulmonary Mycobacterium avium complex disease 133Statistical analysis
Data were analyzed using standard methods. In all
cases, statistical significance was defined as a
two-tailed test with an a of 0.05. All statistical
calculations were performed using the SAS
System for Windows (release 9.0; SAS Institute,
Cary, NC). Additional information on the sequential
design and all analyses is available in the online
supplement.Results
Background
From April 1998 to December 2004, 160 HIV-
negative patients were newly diagnosed with
pulmonary MAC disease at 11 hospitals. None of
them were previously treated with macrolide
antibiotics (CAM or AZM) for pulmonary MAC disease
and no in vitro susceptibility studies for antituber-
culous drugs including macrolide antibiotics were
previously done on any of the MAC isolates from any
of these patients. Among the 160 patients, 14
patients were considered ineligible because of
difficulty in visiting the hospital regularly (geo-
graphic distance). However, the remaining 146
patients (71%) fulfilled the eligibility criteria and
were enrolled in this protocol. They were randomly
divided into patients receiving SM (73 patients,Assessed for eligibility
(n=160)
Did not meet
inclusion criteria
(n=14)
Randomization(n=146)
A group
(n=73)
B group
(n=73)
Analyzed
(n=73)
Analyzed
(n=73)
Figure 1 Flow diagram of progress through the phases of
this study.group A) and not receiving SM (73 patients, group B)
(Fig. 1). Table 2 lists the backgrounds of the
two groups. No significant differences were found
in age, gender, smoking habits, chronic alcoho-
lism, underlying diseases (group A and group B,
respectively): respiratory diseases (27 versus 29),
non-respiratory diseases (16 versus 18), and corti-
costeroid administration (3 versus 4). Antitubercu-
lous drugs were administered before admission (16
versus 14). SM was administered to 3 patients in
group A and 3 patients in group B for treatment of
pulmonary tuberculosis. Table 3 shows the clinical,
microbiological and radiological findings at study
entry. No significant differences were noted in
clinical symptoms, identified pathogens and exten-
sion, location, and characteristics of the lesions on
radiological findings such as bronchiectasis and
cavity.Microbiological efficacy
Sputum conversion rate (Table 4)
Sputum conversion rates were separated into two
groups; group A (with SM, 73 cases) and group B
(without SM, 73 cases). Subsequently, the rate of
group A (71.2%) significantly improved compared
with that for group B (50.7%). The sputum conver-
sion rate revealed a significant difference between
groups A and B in the two strains (M. avium and M.
intracellulare), but no differences between the
two strains. Regarding the existence of underlying
respiratory diseases, there was a significant differ-
ence between patients with underlying respiratory
diseases and those without underlying respiratory
diseases in both groups. Sputum conversion rates
were better in patients in group A without under-
lying respiratory diseases than those in group B
without underlying respiratory diseases. They were
also better in patients in group A with underlying
respiratory diseases than those in group B with
underlying respiratory diseases. As for extension of
the lesion on radiological findings, there was a
significant difference depending on the extension
of the lesion in groups A and B. There was a
significant difference in patients with extension of
the lesion within one-third of the unilateral lung
field between groups A and B, and there was also a
significant difference in patients with extension of
the lesion within the unilateral lung field between
the two groups. There was also a significant
difference in patients with extension of the
lesion within bilateral lung fields. There were no
significant differences in radiological characteristic
findings such as bronchiectasis and cavity in
groups A and B.
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Table 2 Backgrounds of 146 cases with pulmonary MAC disease.
A (n ¼ 73) B (n ¼ 73) P-value
Age (years) 63.8710.6* 66.6710.8 NS
Gender (male/female) 26:47 28:45 NS
Smoking habit (+) 30(41.1%) 33(45.2%) NS
Chronic alcoholism 8(11.0%) 9(12.3%) NS
Underlying disease 43(58.9%) 47(64.4%) NS
Respiratory disease 27(37.0%) 29(39.7%) NS
Non-respiratory disease 16(20.9%) 18(24.7%) NS
Corticosteroid administration 3(4.1%) 4(5.5%) NS
Previously healthy 30(41.1%) 26(35.6%) NS
Prior antituberculous drugs before admission 16(21.9%) 14(19.2%) NS
Table 3 Clinical findings of 146 cases with pulmonary MAC disease.
Clinical symptoms A (n ¼ 73) B (n ¼ 73) P-value
Continuous cough 50(68.5%) 48(65.8%) NS
Weight loss 12(16.4%) 13(17.8%) NS
Hemosputum or hemoptysis 31(42.5%) 33(45.2%) NS
Fever 20(27.4%) 18(24.7%) NS
Microbiological findings
Mycobacterium avium 38(52.1%) 36(49.3%) NS
Mycobacterium intracellulare 35(47.9%) 37(50.7%) NS
Radiological findings
Extension of the lesion
Within one-third of unilateral lung field 31(42.5%) 33(45.2%) NS
Within unilateral lung field 34(46.5%) 32(43.8%) NS
Over unilateral lung field 8(11.0%) 8(11.0%) NS
Location of the lesion
Right 14(19.2%) 16(21.9%) NS
Left 8(10.9%) 7(9.6%) NS
Bilateral 51(69.9%) 50(68.5%) NS
Characteristic findings
Bronchiectasis 46(63.0%) 48(65.8%) NS
Cavity 39(53.4%) 42(57.5%) NS
With repetition.
Y. Kobashi et al.134Sputum relapse rates (Fig. 2)
The sputum relapse rates were separated into two
groups. There was no significant differences be-
tween group A (30.8%) and group B (35.1%), or in
the sputum relapse rates in relation to the two
strains of M. avium and M. intracellulare, the
existence of underlying respiratory diseases, or
extension of the lesion on radiological findings.Clinical efficacy (Tables 5 and 6)
The overall outcome of both regimens was as
follows: improved in 52 patients (35.6%), un-changed in 53 (36.3%), worsened in 37 (25.4%)
and death in 4 (2.7%). The clinical improvement,
when the two groups were considered separately
(with and without SM), was better in group A than
in group B with regard to the microbiological
findings, underlying respiratory diseases and radi-
ological findings, but there were no significant
differences. There was no significant difference in
clinical improvement between the two strains of M.
avium and M. intracellulare in groups A and B. With
regard to the existence of underlying respiratory
diseases, there was no significant difference be-
tween patients with underlying respiratory diseases
and those without them in the two groups. Finally,
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Table 4 Sputum conversion rate for pulmonary MAC disease at the completion of treatment between group A
and B.
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total
(n=89)
N.S. : not significant
Figure 2 Sputum relapse rate for pulmonary MAC disease
at the completion of treatment.
Combined therapy for pulmonary Mycobacterium avium complex disease 135regarding extension of the lesion on radiological
findings, there were no significant differences
between the patients in the two groups having a
lesion within one-third of the unilateral lung field,
within the unilateral lung field, or within the
bilateral lung field. There were also no significant
differences in radiological characteristic findings
such as bronchiectasis and cavity between the two
groups.Drug susceptibility test
A test of drug susceptibility to SM was performed on
strains isolated from73 cases in group A. Among
them, 38 strains (52%) were susceptible, 15 (21%)
were intermediate, and 20 (27%) were resistant to
SM. There were no significant differences in the
sputum conversion rate of the patients infectedwith susceptible strains (28 of 38; 74%), intermedi-
ate strains (10 of 15; 67%), and resistant strains (14
of 20; 70%). The drug susceptibility to SM of
patients who obtained clinical improvement (31
patients) who were susceptible was 18 of 31, 58%,
intermediate 6 of 31, 19%, and resistant 7 of 31,
23%. The drug susceptibility to SM of patients who
could not obtain clinical improvement (44 patients)
who were susceptible was 20 of 44, 45%, inter-
mediate 9 of 44, 20%, and resistant 15 of 41, 34%.Adverse reactions
Adverse reactions, separated into the two groups,
are shown in Table 7. In group A, adverse reactions
appeared in 18 of 73 patients (24.7%) (including
vertigo in three), while in group B, adverse
reactions appeared in 15 of 73 patients (20.5%).
However, there were no severe and irreversible
adverse reactions or abnormal laboratory findings.
There were no significant differences between the
two groups with regard to the adverse reaction
appearance rate and abnormal laboratory findings.
The overall adverse reaction appearance rate was
22.6%.Current status
The median duration of administration was
27.677.8 months (24–36 months) in group A and
28.478.0 months (24–42 months) in group B. The
median duration of follow-up was 15.674.8 months
(12–36 months) in group A and 16.475.0 months
(12–36 months) in group B.
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Y. Kobashi et al.136The mortality rates of both groups were com-
paratively good, 2.7% for group A and 2.7% for
group B. The causes of death were advanced
pulmonary MAC disease in one and complicating
bacterial pneumonia in 1 patient in both groups A
and B. All of the patients who died in both groups
were elderly and had a past history of healed
pulmonary tuberculosis.Table 7 Adverse reactions and abnormal laboratory find
A (n ¼ 73) B (n ¼ 73)
Adverse reactions
18(24.7%) 15(20.5%)
Appearance rate items
Liver dysfunction 4 Liver dysfunction
Vertigo 3 Gastrointestinal s
Gastrointestinal symptom 3 Visual disturbanc
Visual disturbance 2 Eruption
Eruption 2 Fever
Fever 2
Eruption+gastrointestinal 1
Symptom
Fever+liver dysfunction 1
Table 5 Pulmonary MAC disease outcome.
A (n ¼ 73) B (n ¼ 73) Total
(n ¼ 146)
Improving 31 (42.5%) 21 (28.8%) 52 (35.6%)
Unchanging 25 (34.2%) 28 (38.4%) 53 (36.3%)
Worsening 15 (20.6%) 22 (30.1%) 37 (25.4%)
Death 2 (2.7%) 2 (2.7%) 4 (2.7%)
Table 6 Clinical improvements for pulmonary MAC dise
and B.The clinical course of 31 patients (42.5%) in group
A which showed clinical improvement worsened in
15 (48.4%) within 1 year after the completion of
treatment. The time between sputum conversion
and relapse was 3.671.2 months in group A. The
treatment of these patients thereafter was as
follows: the same treatment in 9 patients, new
quinolone (levofloxacin) administration in four, and
surgical operation in two. Five of the 15 patients
responded to the salvage regimen and obtained
clinical improvement. The clinical course of 21
patients (28.8%) in group B who had clinical
improvement worsened in 11 (52.4%) within 1 year
after the completion of treatment. The time
between sputum conversion and relapse was
3.271.2 months. The treatment of these patients
was as follows: treatment including SM in 8
patients, new quinolone administration in two,ings.
Total (n ¼ 146)
33(22.6%) 9
5 Liver dysfunction
ymptom 4 Gastrointestinal symptom 7
e 3 Visual disturbance 5
2 Eruption 4
1 Vertigo 3
Fever 3
Eruption+gastrointestinal 1
Symptom
Fever+liver dysfunction 1
ase at the completion of treatment between group A
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Combined therapy for pulmonary Mycobacterium avium complex disease 137and surgical operation in one. Four of 11 patients
responded to the salvage regimen and obtained
clinical improvement.A
(n=73)
B
(n=73)
total
(n=146)
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N.S. : not significant
Figure 3 Clinical improvement for pulmonary MAC
diseases at the completion of treatment.Discussion
Nontuberculous mycobacterial diseases have been
divided into two groups due to the response to
treatment using antituberculous drugs: one consists
of diseases caused by M. kansasii and M. szulgai,
which show clinical characteristics resembling M.
tuberculosis which has shown a good response to
treatment using antituberculous drugs. The other
consists of ones caused by MAC and M. fortuitum,
which show clinical characteristics resembling
nontuberculous mycobacteria, which have shown
no response to treatment using antituberculous
drugs. The treatment of pulmonary MAC disease
was at first difficult because there were no
antibiotics available having a complete bactericidal
effect with the usual dosage, there was no definite
standard drug sensitivity examination in vitro, and
there was no parallel between the results of drug
sensitivity examinations in vitro and the clinical
effect in vivo. Although the ATS proposed original
guidelines concerning the treatment for nontuber-
culous mycobacterial diseases in 1990, it empha-
sized that it was not useful to employ the drug
sensitivity examination convienient for tuberculosis
for the treatment of nontuberculous mycobacterial
diseases except to check RFP sensitivity for
M. kansasii.6 For these reasons, the treatment of
pulmonary MAC disease has largely depended on
the experience of respiratory specialists in isolating
the causative microorganisms, not on the results of
drug sensitivity examinations. The ATS finally
recommended combined therapy using RBT or RFP,
EB, CAM or azithromycin (AZM) and SM as the
treatment guidelines for pulmonary MAC disease in
1997.4 Among these guidelines, SM was recom-
mended for use for extensive pulmonary MAC
disease intermittently (two or three times per
week) for the first 2–3 months of therapy. The exact
dose of SM in the recommended multidrug regimen
may depend on the patient’s age and weight
(0.75–1.0 g per once). We decided on a dose of SM
of 15mg/kg three times per week because there
were no patients with renal dysfunction in group A.
However, although SM was employed three times
per week at a dose of 15mg/kg in this study, we had
to carry out dose finding prospective study of SM
afterwards to decide appropriate daily dose or
frequency of SM. We also had to perform a double-
blind comparative study using other drugs such as
new quinolone with SM to confirm the clinicalefficacy for pulmonary MAC disease compared with
that of other drugs. No previous reports have
compared CAM-containing regimens with and with-
out an aminoglycoside. Therefore, we performed
the first prospective double-blind randomized trial
to make sure of the utility of SM for the treatment
of pulmonary MAC disease.
Subsequently, although there were no significant
differences in the patients’ backgrounds and the
severity of pulmonary MAC disease in either group,
the sputum conversion rate in group A (with SM)
was significantly higher than that in group B
(without SM), as shown in Table 4. As for the
sputum relapse rate and clinical improvement,
although there were no significant differences
between the groups, group A showed better results
than group B, as shown in Fig. 2 and Tables 5 and 6.
The higher clinical efficacy observed with the
addition of SM may not be related to the MIC of
SM in vitro. In this study, there were cases with a
low MIC of SM in which efficacy was not high and
there were also cases with a good response in spite
of a high MIC of SM in group A. Wallace et al.
reported a good relationship between microbiolo-
gical or clinical efficacy and the drug sensitivity
test with CAM alone,3,7,8 Iseman reported 9 that in
vitro susceptibility testing and therapeutic drug
monitoring of other antituberculous drugs contain-
ing CAM is also useful to optimize efficacy and
reduce toxicity. These results suggest both the
possibility of additive or synergistic effects with
other drugs due to SM or of partial effects for
polyclonal MAC infections. It is assumed that all
patients had macrolide antibiotics (CAM or AZM)
susceptible MAC isolates because there were no
patients who were previously treated with macro-
lide antibiotics.(Fig. 3)
Regarding side effects, such as ototoxicity or
renal toxicity due to SM, irreversible problems were
fortunately not detected in any patients in either
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Y. Kobashi et al.138group. Vertigo appeared in 3 patients (4%) in group
A, but it was not severe and the administration of
SM has been continued. However, because ototoxi-
city due to SM is often irreversible, patients
receiving SM should be instructed about the signs
and symptoms of toxicity (unsteady gait, tinnitus,
diminished hearing) at the start of therapy and
again on subsequent visits, with discontinuation or
decrease in dosage or frequency if suggestive signs
of toxicity occur. There were no significant differ-
ences in the appearance rate or items between the
groups, as shown in Table 7.
Finally, because the method of assessment was
restricted to the sputum conversion rate of MAC
strains before and after treatment in previous
reports,2,10 we believe it is difficult to grasp the
clinical efficacy of the treatment on patients accord-
ing to the ATS guidelines from the assessments made in
other reports. Therefore, we carried out assessment of
clinical improvement based on the clinical symptoms
and/or the extent of lesions on chest roentogenograms
and chest CT instead of including the subjective
assessments of several respiratory specialists.
In conclusion, we support treatment including SM
according to both guidelines (ATS and JST) for patients
with pulmonary MAC disease without HIV infection
based on the findings of this randomized study
because there were no irreversible major side effects
due to SM. However, as we have not been able as yet
to clarify the mechanism, which makes SM effective
against MAC strains, further studies are required.References
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